Minocycline

It was possible to relate Retzius lines to a known-period interval in one section Fig. 7 ; . In this case, a pair of minocycline lines was identified in the cervical enamel and traced to the surface, representing 28 days of enamel formation. Six complete Retzius line intervals seven lines in total ; plus four cross-striations were seen between these two labels. This suggests that each Retzius line interval represents 4 days, which is consistent with observations made on cross-striations between individual pairs of Retzius lines in this individual. Where it was possible to make counts, the number of crossstriations between pairs of Retzius lines was equal within a section, tooth and or individual. This is consistent with several large studies on human dentitions e.g. Beynon, 1992; FitzGerald, 1996; Reid et al. 2002. Sometimes, when the medication wears off, the patient is awakened by a sensation of uncomfortable warmth and experiences pronounced diaphoresis. Table 1. Characteristics of the subjects included in the study. Subjects 1 2 3 Mean SD Non smokers Sex & Age M-23 M-33 M-24 M-25 M-28 M-24 M-25 M-29 M-26 M-42 M-38 M-26 M-30 M-46 29.92 7.23 Height cm ; 178 170 172 FEV1 % pre. 101 98 114 Sex & Age M-36 M-28 M-46 M-48 M-34 M-49 M-29 M-57 M-50 M-38 M-37 M-29 M-33 M-39 39.5 9.06 188 Smokers Height cm ; FEV1 % pre. 88 87 82 Smoking P Y 12 and meloxicam. Ann pharmacother 2005; 8-92 chan aw, moliterno dj, berger pb, stone gw, dibattiste pm, yakubov sl, et al triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the do tirofiban and reopro give similar efficacy outcome trial target. Claim cannot be paid unless the patient was granted retroactive eligibility or you were not aware the patient had Medicaid until after a year from the date of service. Either attach a copy of the patient's letter from DHHS County Medicaid Office giving the retroactive dates to the ECF and mail it to your program representative or attach a note stating the date you were informed of the patient's Medicaid benefits. Refer to the timely filing guidelines in the appropriate section of your provider manual. UB CLAIM: Claims for payment of Medicare coinsurance and deductible amounts must be received and entered into the claims processing system within two years from the date of service or date of discharge, or six months following the date of Medicare payment, whichever is later. NURSING HOME PROVIDERS: Contact your program representative and mebendazole, for example, minocycline hair loss.

Consumers, dentists and medical doctors should be aware of the possible tooth staining effects of minocycline therapy.

Deplatt clopidogrel plavix diamicron mr gliclazide tibofem livial tibolone aciclovir generic zovirax carafate sucralfate ciproxin cipro ciproflaxin coversyl aceon perindopril epivir lamivudine 3tc epivir epivir-hbv imitrex sumatriptan imigran retin-a micro tretinoin avita renova distaclor ceclor cefaclor prepulsid propulsid cisapride sporanox itraconazole apo-nadolol nadolol bromocriptine parlodel doxine doxycycline losec prilosec serzone nefazodone slow-k potassium chloride minoxidil headway nizoral ketoconazole synermox augmentin clamycin klarcid clarithromycin biaxin panadine codeine aropax paxil lipicor atorvastatin lipitor minomycin minocycline minocin oral bupropion zyban wellbrutin sr celebrex celecoxib cozaar losartan warning : main popular ; : failed to open stream: no such file or directory in home virtual site95 fst var site on line 102 warning : main ; : failed opening 'popular ' for inclusion include path '.

Question 88: answers l j k tricuspid regurgitation is associated with endocarditis in drug addicts and ponstel. Fig. 6-38. Allergic contact dermatitis from hand cream. Hand dermatitis can result from exposure to foods, toxicodendrons, oils, solvents, metals, topical medications, rubber gloves, soaps, or detergents, for instance, minocycline uti. Temporary Work Permits Temporary work permits are usually valid for a specified job, employer and time period. It is incumbent upon the physician to apply for a renewal extension of the work permit before the expiration date. To do so, the physician must submit the appropriate application to the immigration authorities at the Citizenship and Immigration Canada CIC ; Case Processing Centre CPC ; in Vegreville, Alberta. Applications may be downloaded from cic.gc or requested from 1-888-242-2100 Human Resources and Skills Development HRSD formerly HRDC ; validation is required for the initial work permit and for any subsequent extension renewal. The physician must initiate the immigration work permit application process, and the employer must initiate the process of obtaining HRSD validation. Permanent Resident Applications Generally speaking Canadian immigration legislation requires that applications for permanent resident landed immigrant ; status be submitted through a Canadian immigration office outside of Canada. Many physicians in Manitoba submit applications to the Canadian Consulate in Buffalo, New York. These applications are normally processed in the Skilled Worker category, and the processing time may exceed 24 months. During this time you must ensure that your temporary work permit does not expire. You may wish to obtain permanent HRSD validation from your employer in support of your application for permanent resident status. To do so, your employer must submit an application to HRSD requesting permanent validation. This request must first be approved by Manitoba Health. Manitoba Health uses the following guidelines in considering approval of a permanent validation permit, in support of a physician's application for permanent resident status: that you have worked for your employer for 2 years; that you have indicated a commitment to remaining in the community, or in Manitoba e.g., purchased a home, bought into a medical practice, become involved in your community that you have initiated action to achieve full licensure with the College of Physicians and Surgeons of Manitoba and melatonin. DOXYCYCLINE Doxycycline is a semisynthetic broad-spectrum tetracycline antibiotic that is derived from oxytetracycline. It has advantages over tetracycline in that it is more completely absorbed, maintains effective blood levels for longer periods of 14-24 hour half-life ; and is excreted more slowly. Labeled uses include chlamydial and mycoplasmal infections, gonorrhea and syphilis in penicillin-allergic patients, rickettsial diseases, and for exacerbations of chronic bronchitis. Dermatologists have used it for acne for many years. Sweet's syndrome Sweet's syndrome acute febrile neutrophilic dermatosis ; is a cutaneous condition characterized by fever, neutrophilic leukocytosis, and mucocutaneous papules and plaques that demonstrate neutrophil-rich infiltrates of the dermis. Sweet's syndrome rapidly responds to oral corticosteroids but relapses often occur following discontinuation of therapy. A variety of steroid-sparing therapies have been tried with varying degrees of success including potassium iodide, clofazimine, indomethacin, colchicine, and dapsone. Joshi and coworkers first reported two patients with Sweet's syndrome treated with doxycycline in 1993. Both patients were treated with doxycycline 100 mg po bid and demonstrated a noticeable response occurring within 1-2 weeks and complete clearing within 4 weeks. I have had similar results achieving complete clearing in 3 patients and partial clearing in 2 patients. The proposed mechanism is thought to be due to the inhibition of neutrophil chemotaxis. I have also used minocycline with similar results using the same rationale. Of interest, is that minocycline has also been reported to induce Sweet's syndrome which could produce confusion. Reference: 1. Joshi RK, et al: Successful treatment of Sweet's syndrome with doxycycline. Br J Dermatol 128: 584-586, 1993. UMB filed a provisional patent application for this invention on March 16, 2004. Subsequently, UMB concurrently filed PCT and U.S. applications on March 16, 2004. Dr. Shapiro's research involved the use of resources purchased under a Cancer Grant. The specific MLK inhibitor used by Dr. Shapiro was acquired from a colleague at another institution. This material was originally acquired from Cephalon, Inc. under an Academic Materials Transfer Agreement, made effective November 14, 2002 between Cephalon and the other institution. Under that agreement, Cephalon retained certain rights to inventions and discoveries made using its material. As a result, UMB negotiated a Materials Transfer Agreement, effective October 22, 2004, wherein Cephalon, Inc. is granted a worldwide, paid-up and royalty-free, exclusive license to develop and commercialize the invention. The agreement allows UMB to continue to seek patent protection for the invention and permits Dr. Shapiro to continue research related to his invention. Invention #2: "Single Nucleotide Polymorphism Associated with Stroke, " invented by Drs. Steven Kittner, Braxton Mitchell, John Cole and Colin Stine of UMB; co-invented with collaborators Quing Song, Gary Gibbons and Patrick Thomas at Morehouse College. Dr. Cole is a member of the faculty in UMB's School of Medicine and the Department of Neurology. A portion of the funds used in the research that led to this invention was derived from the Other Tobacco-Related Diseases Research grant through the Maryland CRFP. This invention identifies a Single Nucleotide Polymorphism SNP ; associated with Stroke susceptibility, particularly in young adult smoking populations. A "SNP" is a single base change in the DNA coding sequence of a gene. The single base change usually affects the protein structure and or function encoded by the gene that possesses the SNP. The inventors identified a novel SNP in the PDE4D gene that strongly correlates to early onset of stroke in persons of multi-cultural, ethnic and gender backgrounds. The strongest correlation appeared in the African-American segment of the test population. The invention was disclosed to ORD on October 7, 2004 and was reviewed internally by the Technology Commercialization Group. The inventors presented their invention to UMB's Scientific Review Committee on September 14, 2005. ORD determined at that time to retain title to this invention. UMB filed a provisional patent application based on the initial invention disclosure on December 22, 2004. Subsequently, as additional data became available to the researchers, they identified a new SNP that was more strongly associated with members of the smoking population than the original SNP identified in the first provisional patent application. Therefore, UMB filed another provisional patent application incorporating this new data on October 28, 2005. UMB filed yet another provisional patent application on November 3, 2005 to include new figures provided by the inventors subsequent to the October 28 filing. UMB plans to file additional patent applications on or before the expiration of the second provisional patent application October 28, 2006 and metaproterenol. TABLE 2. Distribution of Diagnoses Between Baseline and Treatment Group * Baseline Diagnostic category Cardiac Respiratory Other medical Septic shock Neurologic Trauma General surgical No. of patients 169 115 113 Age y ; 72 61-84 ; 73 59-83 ; 64 49-80 ; 75 56-84 ; 63 50-77 ; 45 27-67 ; 72 57-78 ; APACHE II score 17 11-24 ; 21 17-26 ; 16 12-22 ; 28 22-36 ; 12 8-21 ; 13 8-23 ; 12 9-18 ; No. of patients 175 125 117 Treatment Age y ; 75 58-81 ; 74 60-80 ; 58 44-77 ; 72 62-82 ; 58 45-71 ; 35 26-54 ; 72 60-79 ; APACHE II score 17 11-23 ; 20 16-26 ; 15 11-23 ; 25 21-32 ; 11 7-17 ; 8 4-19 ; 12 9-16. Doxycycline mic range: 06– 125 mg l ; and minocyclinr mic range: 06– 125 mg l ; had a moderate activities against genitalium -positive non-gonococcal urethritis and methoxsalen and minocycline. MEASURE IP OWNER1 NUMERATOR Doxycycline Erythromycin Ery ESucc Sulfisoxazole Flomefloxacin Gatifloxacin Levofloxacin Loracarbef Minocycljne Ofloxacin Penicillin VK Penicillin G Sparfloxacin Sulfisoxazole Tetracycline Trimethoprim Trimethoprim-sulfamethoxazol Medical Record Collection: Electronic Health Record EHR ; users may opt to use this methodology or the electronic data collection methodology described above. EHR users who have information on drugs prescribed and not dispensed may opt to follow the medical record specifications below but produce data on 100% of their denominator population instead of a sample. Numerator- Documentation in the medical record must include, at a minimum, a note indicating a written prescription for antibiotic medication drug list available ; on the Episode Date. The measure examines one eligible episode per patient. DENOMINATOR 99241-99245, 99271-99275, 9938199385, ; After hours and non emergency urgent care UB-92: 0456 Clinic UB-92: 051X Freestanding Clinic UB-92: 052XProfessional fees-outpatient services UB-92: 0982 Professional fees-clinic, UB-92: 0983 Codes to Identify Emergency Department Visits * UB-92 Type of Bill Codes: 13X, 43X and UB-92 Revenue Codes: 0450, 0451, 0452, or CPT Code: 99281-99285 * Exclude from the denominator patients admitted to the hospital from the ED. Step 2: For each patient identified in step 1, determine all outpatient Episode Dates. Step 3: Exclude Episode Dates where a new or refill prescription for an antibiotic medication was filled 30 days prior to the Episode Date or which was active on the Episode Date. Antibiotic Medications: Amoxicillin Amox Clavulanate Ampicillin Azithromycin Cefaclor Cefadroxil hydrate Cefdinir Cefixime Cefditoren Ceftibuten Cefpodoxime proxetil Cefprozil Ceftriaxone Cefuroxime Cephalexin Ciprofloxacin Clindamycin EXCLUSIONS DATA SOURCE.
Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224; 2 Loma Linda University, Loma Linda, California 92350; and 3 Metra Biosystems, Palo Alto, California 94304; corresponding author Adv Dent Res 12: 71-75, November, 1998 Abstract--The effect of oral minocyclin on osteopenia in ovariectomized OVX ; old rats was examined in this study. Rats were divided into 4 groups: sham-operated, OVX followed by treatment with vehicle, minocycline, or 17 3estradiol. The treatment was initiated one day after OVX and proceeded for 8 wks. OVX reduced bone mineral density BMD ; in the whole femur and in the femoral regions that are enriched in trabecular bone. Treatment with munocycline or estrogen prevented a decrease in BMD. Femoral trabecular bone area, trabecular number, and trabecular thickness were reduced, and trabecular separation was increased by OVX. Treatment with minocycline or estrogen abolished the detrimental effects induced by OVX. OVX also reduced indices that reflect the interconnectivity of trabecular bone, and the loss of trabecular connectivity was prevented by treatment with minocycline or estrogen. Based on the levels of urinary pyridinoline, we showed that the effect of estrogen, but not minocycline. was primarily through its inhibitory effect on bone resorption. Analysis of bone turnover activity suggests that OVX increased parameters associated with bone resorption eroded surface ; and formation osteoid surface, mineralizing surface, mineral apposition rate, and bone formation rate ; . Treatment with minocycline reduced bone resorption modestly and stimulated bone formation substantially. In contrast, treatment with estrogen drastically reduced parameters associated with both bone resorption and formation. We have concluded that oral minocycline can effectively prevent the decrease in BMD and trabecular bone through its dual effects on bone resorption and formation. Key words: Osteoporosis, minocycline, estrogen, bone formation, bone resorption. Presented at the Workshop on the UNon-Antibiotic Properties of Tetracyclines", held November 13-14, 1997, in Garden City, New York, sponsored by the Long Island Jewish Medical Center, CollaGenex Pharmaceuticals, Inc., and the National Institute of Dental Research NIH and oxsoralen.

Discount generic Minocyclin4 online To detect HPV, health care providers look for dysplasia or genital warts. Dysplasia can be detected by Pap smears. They are usually used to check a woman's cervix. They can also be used to check the anus in men and women. A swab is rubbed on the area being checked to pick up some cells. They are smeared on a glass slide and examined under a microscope. A new HPV test called a reflex test is being used to follow up on Pap smear results that are not clear. It can indicate who needs more. Patients with a history of hepatic, renal, or collagen vascular disease. Also, patients with a history of candidal vulvovaginitis should be advised that broad-spectrum antibiotics can permit the vulvovaginitis to recur. Less commonly used antibiotics for acne are the cephalosporins and penicillins, particularly ampicillin. The use of azithromycin as a four- or five-day pulse therapy in women who have monthly premenstrual acne flares has recently gained some interest. Clindamycin and oral sulfonamides are also quite effective oral anti-acne agents. However, the former has been associated with pseudomembranous colitis, and the latter may precipitate severe hypersensitivity reactions. Thus, these agents are not recommended in most situations. TETRACYCLINES The tetracylines are the workhorses in systemic acne therapy. They have the disadvantage of staining teeth in children under age 9, and in fact, they may temporarily stain the teeth of older patients, particularly those with orthodontic braces. When prescribing tetracyclines, the importance of good dental hygiene, including flossing, should be stressed. Tetracyclines may also cause gastrointestinal irritation, phototoxic reactions an increased tendency to sunburn ; , and vulvovaginitis. Generic tetracycline and brand name preparations such as Achromycin and Terramycin are the least expensive of the tetracyclines. These formulations should be taken on an empty stomach one hour before or two hours after meals ; and not with dairy products or compounds that contain divalent cations, such as magnesium, zinc, and calcium--all of which may interfere with absorption. Esophageal irritation may be avoided by taking tetracycline with a full glass of water. Tetracycline has been implicated in the development of benign intracranial hypertension pseudotumor cerebri ; , particularly when it is given concurrently with 13-cisretinoic acid. MINOCYCLINE This antibiotic is more expensive but more effective than plain tetracycline for treating inflammatory acne. Minocycline's excellent absorption allows it to be taken with food, and it causes few, if any, phototoxic problems. It also appears to be less likely to induce candidal vulvovaginitis than plain tetracycline. However, minocycline is more likely than plain tetracycline to cause such side effects as nausea, vomiting, and, in high doses those that approach 200 mg d ; , dizziness due to vestibular dysfunction. Less commonly, long-term treatment with minocycline may cause a reversible bluish hyperpigmentation of the gums and or skin. In rare cases, it is associated with benign intracranial hypertension and hepatitis. Free Minocycline Prolonged survival both by inhibiting caspase-1 and caspase-3 messenger RNA up-regulation, and by decreasing the activity of iNOS 6 ; . Although minocycline-mediated neuroprotection has been extensively reported, no corresponding data are yet available about the potentially beneficial effects of minocycline as a cardioprotective agent against ischemia reperfusion I R ; injury. Therefore, the present study was designed to evaluate the cardioprotective effectiveness and mechanism of action of minocycline during I R injury both in primary cultures of myocytes and in the intact heart.

Prescription Drugs 1. Benzoyl peroxide can cause local skin irritation and can bleach clothing. The preparation to be used should be selected according to skin type, e.g. a very oily skin can tolerate a gel preparation whereas a less oily, fair skin can only tolerate creams. Similarly, if irritation occurs with an alcohol based preparation, change to a water based or cream preparation. Topical retinoids can also cause skin irritation and may tend to aggravate acne in the first weeks of use. Creams are best for dry or fair skin whilst gels are more suitable for oily or dark skin. Topical retinoids are best avoided in women who are at risk of pregnancy. Abrasive agents e.g. Brevoxyl may be used when there are more comedones and can be used in combination with other topical and systemic preparations. Oral tetracyclines can cause gastro-intestinal upset and some can cause skin hyperpigmentation, especially minocycline in prolonged high dose usage. Benign intracranial hypertension is a rare side effect of tetracycline use. Isotretinoin should not be combined with tetracyclines as this may increase the risk of this rare side effect. Tetracyclines can cause discoloration of developing teeth and bones and should not be given under the age of 12 or breastfeeding or where there is a possibility of pregnancy. Tetracyclines are best taken an hour before food or on an empty stomach. Similarly, they should not be taken with milk, dairy products, oral iron or zinc or indigestion remedies as these products may decrease absorption. Dark-colored fruits and vegetables and meloxicam. Encephalitis FIGURE 1 ; .12 In contrast, 3 of 5 minocycline-treated animals did not develop encephalitis while the remaining 2 macaques had only mild encephalitis. This decreased incidence of moderate and severe encephalitis in the minocycline-treated macaques was statistically significant P .02 ; . To assess the ability of minocycline to suppress SIV-induced CNS inflammation, we quantitated infiltration and activation of macrophages and infiltration of cytotoxic lymphocytes into the CNS, activation of p38 mitogenactivated protein kinase in the brain and expression of -amyloid precursor protein, a marker of axonal degeneration, by quantitative immunohistochemical analysis.12, 25, 27, 28 Minocycljne significantly reduced expression of major histocompatibility complex class II antigens P .03; FIGURE 2A ; , indicating suppressed activation of macrophages, endothelial cells, or both in the brain. Decreased infiltration and activation of macrophages in minocyclinetreated animals also was suggested by reduced expression of the macrophage marker CD68 P .07, Figure 2B ; . Minocyclinf also reduced the infiltration of cytotoxic lymphocytes into the brain as evidenced by significantly reduced expression of the cytotoxic lymphocyte marker T-cell intracytoplasmic antigen 1 P .03.

Drugs used in the treatment of asthma. In the accelerated breakdown of connective tissues and may lead to conditions such as ulcerative keratolysis. There is increasing experimental and clinical evidence that during corneal injury and inflammation, MMPs play a major role in the proteolytic processes, which can predispose the cornea to perforation.[21] Thus, this study focuses on evaluating the expression of MMPs after the use of commercially available fluoroquinolone eye drops in order to elucidate a relationship between keratolysis, corneal perforation and the use of ophthalmic fluoroquinolone drugs as reported in previous clinical studies.[11] The findings in the current study provide the first evidence that some undesirable effects on corneal wound healing from the use of specific fluoroquinolone eye drops or their use in vulnerable corneal epithelium ; may be secondary to the over-expression of the metalloproteinases. Furthermore, the results of our study clearly demonstrate that the commercial fluoroquinolone ophthalmic agents tested stimulate expression of corneal collagenases MMP1 and MMP-8 ; and gelatinases MMP-2 and MMP-9 ; in normal eyes compared to a negative expression of MMPs in the artificial tear group. Additional studies are required to confirm the exact cellular origin of MMP-8 expressed in corneal tissue, although it is now recognized that cell types other than PMNs can express this collagenase. Recent in vivo and in vitro studies indicate that the pathologic mechanism with fluoroquinolones may be related to significant increases of matrix-degrading proteolytic. Minocycline, like other tetracycline-class antibiotics, crosses the placenta and may cause fetal harm when administered to a pregnant woman.

Medco protects your safety The risks associated with drug-to-drug interactions and drug allergies can be very serious. To protect your safety--whether you use Medco By Mail or medco --Medco checks for potential interactions and allergies. We also send information electronically to participating retail pharmacies. Medco may contact your doctor about your prescription If you are prescribed a drug that is not on your plan's preferred list, yet an alternative planpreferred drug exists, we may contact your doctor to ask whether that drug would be appropriate for you. If your doctor agrees to use a plan-preferred drug, you will never pay more and will usually pay less. Medco protects your privacy Because your privacy is important to us, Medco complies with federal privacy regulations. Medco uses health and prescription information about you and your dependents to administer your plan and to fill your mail-order prescriptions. Your plan may have coverage limits Your SAMBA prescription drug plan has certain coverage limits. For example, prescription drugs used for cosmetic purposes may not be covered, or a medication might be limited to a certain amount such as the number of pills or total dosage ; within a specific time period. If you submit a prescription for a drug that has coverage limits, your pharmacist will tell you that approval is needed before the prescription can be filled. The pharmacist will give you or your doctor a toll-free number to call. If you use Medco By Mail, your doctor will be contacted directly. When a coverage limit is triggered, more information is needed to determine whether your use of the medication meets your plan's coverage conditions. We will notify you and your doctor of the decision in writing. If coverage is approved, the letter will indicate the amount of time for which coverage is valid. If coverage is denied, an explanation will be provided, along with instructions on how to submit an appeal. Controlled substances Federal law prohibits the return of dispensed controlled substances, for instance, minocycline effect. The meeting, chaired by Dr Hilda O'Shea, secretary of PCDS Ireland, ended with a short question and answer session. It would not have been possible without the generous sponsorship of the pharmaceutical companies, the main sponsor Forest Laboratories and co-sponsors; Astellas, Schwarz Pharma and 3M Health Care. Their representatives were on hand during registration and the mid-morning coffee break. Ballymaloe Restaurant is noted for its cuisine, much of the food being produced on the family farm. This was evidenced by the excellent lunch served at the close of proceedings. Dr Ronan O'Sullivan, South Terrace Medical Centre, Cork. Doxycycline achieves much higher tissue concentrations than tetracycline, while minocycline penetrates tissue far more effectively than doxycycline. Table 1. Creatinine clearance, drugs doses and mycophenolate mofetil monitoring of the six patients with neutropenia Patient no. Creatinine clearance ml min 1.73 m2 ; VGC dose mg day ; MMF dose mg day ; MMF area under concentration curve mg h l ; 59.9 78.8 19.78. View complete discussion thread on healthboards 23rd september 2001 just an update. 488. Isolation and structural characterization of novel Rugosin A-like insulinotropic peptide from the skin secretions of Rana saharica frog - Marenah L., Flatt P.R., Orr D.F. et al. [L. Marenah, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine BT52 1SA, United Kingdom] - PEPTIDES 2005 26 11 ; - summ in ENGL Skin secretions of Rana saharica were evaluated for the isolation and characterization of novel insulinotropic peptides. Crude secretions obtained from young adult frogs by mild electrical stimulation of the dorsal skin surface were purified by reversed-phase HPLC yielding 80 fractions. In acute incubations with glucoseresponsive BRIN-BD11cells, fractions 36-43, 46-54 and 57-63 showed the significant 2-8-fold increase in insulin-releasing activity P 0.001 ; compared with 5.6 mM of glucose alone. A pool of fractions 36-43 was subsequently rechromatographed to 28 homogenous peaks out of which 7 were capable of subsequent 1.53-fold increase in insulin release P 0.001 ; . Structural analysis of the non-toxic peptides with greatest insulin-releasing activity was performed by mass spectrometry and Edman degradation. Mass spectrometry analysis of two peaks indicated the molecular masses of 1892.6 and 2930.8 Da. The sequence of the 1892.6-Da peptide was determined as KGAAKGLLEVASCKLSKSC, which has 68% homology with Rugosin A originally isolated from the skin secretion of Rana rugosa. A partial N-terminal sequence was determined for the 2930.8-Da peptide as AVITGACERDVQCGGGTCCAVSLI. These data indicate that the skin secretions of Rana saharica frogs contain novel peptides with insulin-releasing activity. 2005 Elsevier Inc. All rights reserved. Schmitt, L., Berlan, M., et al 1997 ; A comparative study of the effects of yohimbine and anetholtrihione on salivary secretion in depressed patients treated with psychotropic drugs. European Journal of Clinical Pharmacology, 52, 339 342. Pharmacology 52.